SCHEMBL4772347

SCHEMBL4772347

CS(=O)(=O)N(Cc1cccc(Cl)c1Cl)c1ccc(N(C=O)Cc2ccc(C(F)(F)F)nc2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.37
NR1H2 P55055 3/20 0.35
NR1H3 Q13133 3/20 0.35
PTGER1 P34995 1/20 0.35
LMNA P02545 2/20 0.34
POLB P06746 1/20 0.34
TRPM8 Q7Z2W7 3/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
HDAC6 Q9UBN7 2/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
KCNH2 Q12809 1/20 0.33
CNR1 P21554 2/20 0.32
CNR2 P34972 2/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32
RECQL P46063 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5571164 0.93 GAA (0.44) GAANR1H2NR1H3LMNAPOLB
SCHEMBL4772420 0.92 GAA (0.37) GAANR1H2NR1H3PTGER1LMNA
SCHEMBL4770843 0.92 LMNA (0.36) GAANR1H2NR1H3LMNAPOLB
SCHEMBL4770824 0.88 CNR1 (0.35) GAANR1H2NR1H3LMNAPOLB
SCHEMBL4776552 0.86 POLB (0.39) GAANR1H2NR1H3LMNAPOLB
SCHEMBL4771131 0.86 GAA (0.37) GAANR1H2NR1H3POLBTRPM8
SCHEMBL4776872 0.86 RECQL (0.39) NR1H2NR1H3LMNAPOLBHDAC6
SCHEMBL4777509 0.86 CNR2 (0.37) GAANR1H2NR1H3LMNAPOLB
SCHEMBL4771247 0.86 ALDH1A1 (0.42) NR1H2NR1H3LMNAPOLBTRPM8
SCHEMBL4768261 0.86 TRPM8 (0.38) GAATRPM8HDAC6KCNH2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 GAA 466/4885NR1H2 2527/4885NR1H3 2460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.